Table 3 Microvessel Density in TETs of patients in regard to histology, tumor stage and myasthenia gravis.
From: Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors
Variables | Nr. | Absolute Number of Vessels | Tumor Vessel Ratios | ||||
|---|---|---|---|---|---|---|---|
mean ± SEM | mean ± SEM | ||||||
Immature | Mature | Total | Imm./Mat. | Imm./Tot. | Mat./Tot. | ||
WHO Classification | |||||||
MNT | 4 | 121.1 ± 15.8 | 15.8 ± 1.9 | 136.8 ± 14.9 | 8.2 ± 1.6 | 0.88 ± 0.03 | 0.12 ± 0.03 |
A | 14 | 114.5 ± 16.0 | 19.0 ± 3.6 | 133.4 ± 15.8 | 9.8 ± 2.6 | 0.83 ± 0.03 | 0.17 ± 0.03 |
AB | 14 | 115.4 ± 6.9 | 13.7 ± 1.7 | 129.0 ± 6.5 | 10.8 ± 2.0 | 0.89 ± 0.01 | 0.11 ± 0.01 |
B1 | 10 | 87.1 ± 13.4 | 10.0 ± 1.8 | 97.0 ± 12.4 | 15.2 ± 4.8 | 0.86 ± 0.04 | 0.14 ± 0.04 |
B2 | 21 | 82.8 ± 11.6 | 13.5 ± 1.5 | 96.2 ± 11.3 | 10.1 ± 2.9 | 0.82 ± 0.03 | 0.18 ± 0.03 |
B3 | 17 | 52.3 ± 9.5 | 27.7 ± 7.3 | 80.0 ± 11.7 | 3.3 ± 0.8 | 0.64 ± 0.05 | 0.36 ± 0.05 |
TC | 14 | 25.1 ± 2.9 | 29.8 ± 4.8 | 54.9 ± 4.7 | 1.1 ± 0.2 | 0.47 ± 0.04 | 0.53 ± 0.03 |
p - valuea | <0.001 | 0.008 | <0.001 | 0.005 | <0.001 | <0.001 | |
Masaoka – Koga Tumor Stage | |||||||
I | 23 | 109.6 ± 9.7 | 16.1 ± 2.0 | 125.7 ± 9.9 | 8.8 ± 1.2 | 0.86 ± 0.02 | 0.14 ± 0.02 |
II | 45 | 91.6 ± 7.3 | 13.9 ± 1.3 | 105.5 ± 6.9 | 11.4 ± 1.9 | 0.83 ± 0.02 | 0.17 ± 0.02 |
III | 13 | 41.1 ± 9.2 | 22.4 ± 3.0 | 63.5 ± 10.8 | 2.1 ± 0.5 | 0.60 ± 0.05 | 0.40 ± 0.05 |
IV | 13 | 28.9 ± 3.9 | 38.7 ± 9.7 | 67.6 ± 9.6 | 1.1 ± 0.3 | 0.47 ± 0.05 | 0.53 ± 0.05 |
p - valuea | <0.001 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | |
Myasthenia Gravis | |||||||
positive | 29 | 77.6 ± 6.5 | 22.8 ± 9.3 | 106.6 ± 9.3 | 7.2 ± 1.5 | 0.76 ± 0.04 | 0.24 ± 0.04 |
negative | 68 | 83.8 ± 9.0 | 17.4 ± 1.4 | 95.0 ± 6.0 | 8.2 ± 1.3 | 0.75 ± 0.02 | 0.25 ± 0.02 |
p - valueb | 0.594 | 0.272 | 0.295 | 0.664 | 0.803 | 0.803 | |